Compare iShares MSCI Indonesia ETF (EIDO) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Organon & Co. Common Stock — how do they compare? iShares MSCI Indonesia ETF trades at $11.53 (market cap $398.16M), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 9.1× iShares MSCI Indonesia ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares MSCI Indonesia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 76 Days and Organon & Co. Common Stock for 0 Days on average.
| EIDO | OGN | |
|---|---|---|
Market Cap | $398.16M | $3.62B |
Volume | 1,172,701 | 2,892,999 |
52-Week High | $19.22 | $13.81 |
52-Week Low | $10.80 | $5.70 |
Typical Hold Time | 76 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO trades at $11.71, up 0.34% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings but faces selling pressure. Recent news highlights declining trading volume and questions about Indonesia's commodity benefits. Financial ratios remain undisclosed in current data.
Outlook remains cautious due to technical downtrend and sector concentration risks. The 44% financials weighting and modest EPS growth limit upside potential. Seasonal patterns may offer brief relief, but structural challenges persist for sustained appreciation.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
